Your browser is no longer supported. Please, upgrade your browser.
Settings
NVS Novartis AG daily Stock Chart
NVS [NYSE]
Novartis AG
Index- P/E31.45 EPS (ttm)2.74 Insider Own9.30% Shs Outstand2.64B Perf Week0.68%
Market Cap227.11B Forward P/E16.48 EPS next Y5.23 Insider Trans-0.01% Shs Float2.48B Perf Month3.46%
Income6.54B PEG5.66 EPS next Q1.24 Inst Own11.10% Short Float0.08% Perf Quarter-0.21%
Sales49.18B P/S4.62 EPS this Y-2.80% Inst Trans-2.18% Short Ratio1.19 Perf Half Y15.85%
Book/sh29.70 P/B2.90 EPS next Y10.04% ROA4.90% Target Price89.50 Perf Year5.03%
Cash/sh- P/C- EPS next 5Y5.55% ROE9.10% 52W Range66.93 - 86.90 Perf YTD18.29%
Dividend2.72 P/FCF46.95 EPS past 5Y-5.80% ROI7.30% 52W High-0.85% Beta0.75
Dividend %3.16% Quick Ratio0.80 Sales past 5Y-3.60% Gross Margin65.40% 52W Low28.73% ATR0.81
Employees119000 Current Ratio1.00 Sales Q/Q-1.50% Oper. Margin16.10% RSI (14)60.04 Volatility0.89% 0.76%
OptionableYes Debt/Eq0.44 EPS Q/Q11.10% Profit Margin13.30% Rel Volume1.62 Prev Close84.94
ShortableYes LT Debt/Eq0.33 EarningsOct 17 BMO Payout98.40% Avg Volume1.68M Price86.16
Recom2.30 SMA201.76% SMA502.12% SMA2009.98% Volume2,721,428 Change1.44%
Jul-26-17Upgrade Morgan Stanley Underweight → Overweight
Jul-05-17Downgrade Credit Suisse Neutral → Underperform
Mar-09-17Initiated Liberum Buy
Mar-08-17Upgrade Societe Generale Hold → Buy
Mar-07-17Downgrade Exane BNP Paribas Neutral → Underperform
Jan-11-17Downgrade Credit Suisse Outperform → Neutral
Nov-10-16Upgrade Argus Hold → Buy
Oct-10-16Reiterated Chardan Capital Markets Buy $95 → $92
Sep-20-16Initiated Chardan Capital Markets Buy $95
Apr-12-16Downgrade Morgan Stanley Equal-Weight → Underweight
Mar-23-16Downgrade Leerink Partners Outperform → Mkt Perform
Jun-22-15Upgrade Bryan Garnier Neutral → Buy
Nov-16-09Initiated Deutsche Securities Buy
Nov-12-09Initiated Barclays Capital Underweight $48
Sep-30-09Upgrade Citigroup Hold → Buy
Sep-15-09Upgrade Jefferies & Co Hold → Buy
Jul-17-09Upgrade JP Morgan Neutral → Overweight
Mar-17-09Initiated Credit Suisse Neutral
Feb-27-09Reiterated Credit Suisse Neutral $14 → $7
Jan-26-09Initiated Jefferies & Co Hold
Sep-22-17 04:00PM  Oddly, Juno Therapeutics Is Jumping 11.3% Today Motley Fool
10:37AM  How Is Novartiss Subsidiary Sandoz Positioned after 1H17? Market Realist
09:06AM  How Is Novartiss Subsidiary Alcon Positioned after 1H17? Market Realist
07:36AM  Gilenya and Entresto Could Keep Boosting Novartiss Revenue Growth Market Realist
07:30AM  [$$] Alnylam's New Medicine To Enter Pricing Debate The Wall Street Journal
07:03AM  Juno Therapeutics Inc (JUNO) Stock: To Buy or Not to Buy? InvestorPlace
07:00AM  Corporate News Blog - Novartis Receives ECs Approval for Rydapt; Set to Treat FLT3-Mutated Active Myeloid Leukemia ACCESSWIRE
04:22AM  Novartis's $475,000 Price on Cancer Therapy Meets Resistance Bloomberg
Sep-21-17 03:30PM  Why Gilead Sciences Is Flying High With Kite Forbes
12:01PM  Immunize Juno Therapeutics Inc (JUNO) Stock With This Trade InvestorPlace
10:36AM  How Did Novartiss Established Medicines Perform in 1H17? Market Realist
10:15AM  How is the Age-Related Macular Degeneration Space Faring Now? Zacks
09:06AM  How Are Novartiss Respiratory Drugs Positioned after 1H17? Market Realist
07:36AM  Investor Updates on Novartiss Immunology and Dermatology Portfolio Market Realist
Sep-20-17 02:32PM  Novartis Poised to Grow on Oncology Portfolio & Biosimilars Zacks
11:19AM  Why Are Cancer Drugs So Expensive? Motley Fool
10:36AM  Why Cosentyx Could Significantly Drive Novartiss Revenue Growth Market Realist
09:06AM  How Does Novartiss Ophthalmology Portfolio Look? Market Realist
07:38AM  How Novartiss Promacta, Votrient, and Jakavi Performed in 1H17 Market Realist
Sep-19-17 10:38AM  An Update on Novartiss Sandostatin, Afinitor, and Exjade Market Realist
09:10AM  How Are Novartiss Blockbuster Drugs Gleevec and Tasigna Positioned? Market Realist
08:08AM  An Update on Novartiss Tafinlar and Mekinist post 1H17 Market Realist
Sep-18-17 06:03PM  Novartis Announces Positive Data on Urticaria Drug Xolair Zacks
05:36PM  Kisqali Could Significantly Boost Novartiss Revenue Growth Market Realist
04:07PM  How Did Novartis Perform in 1H17? Market Realist
02:19PM  How Is Novartiss Lucentis Positioned after 1H17? Market Realist
02:19PM  What Analysts Recommend for Novartis in September 2017 Market Realist
Sep-15-17 02:21PM  AbbVie's New Hepatitis C Drug Chipping Away At Gilead's Share Investor's Business Daily
06:03AM  How Much Does It Really Cost to Develop a Cancer Drug? Motley Fool
03:00AM  Novartis Sees IBD RS Rating Rise To 72 Investor's Business Daily
Sep-14-17 11:00AM  Novartis Announces Long-Term Data on Psoriasis Drug Cosentyx Zacks
Sep-12-17 03:33PM  3 Things Amgen Inc.'s Management Just Said That You'll Want to Know Motley Fool
11:27AM  Novartis' BLA for Biosimilar of Rituxan Accepted by the FDA Zacks
Sep-11-17 07:30PM  5 Ways To Play The Biotech Bull Market Oilprice.com
04:02PM  5 Tough Questions for Gilead Sciences About the Kite Pharma Acquisition Motley Fool
09:22AM  Foreign Stock Roundup: HMC Agrees on $605M Takata Air Bag Settlement, Narasimhan to Head Novartis Zacks
Sep-10-17 06:05PM  Novartis posts a win, Roche a flop in skin cancer trials Reuters
04:19AM  Lilly takes on Pfizer, Novartis with new breast cancer drug data Reuters
Sep-08-17 11:07AM  [$$] Investors Chronicle: Redrow, Oxford BioMedica, Halfords Financial Times
08:25AM  Pharma Stock Roundup: Lilly to Cut Jobs, Streamline Operations, NVS CEO to Step Down in 2018 Zacks
07:38AM  Understanding Mercks Valuation after 2Q17 Market Realist
03:00AM  Novartis Sees Relative Strength Rating Improve To 75 Investor's Business Daily
Sep-07-17 02:54PM  Are You Buying Gilead Sciences, Inc. for the Wrong Reason? Motley Fool
09:00AM  Departing Novartis CEO Sets His Eyes On Silicon Valley Forbes
06:04AM  5 Things Gilead Sciences' Management Just Said That You'll Want to Know Motley Fool
Sep-06-17 10:30AM  Novartis' (NVS) MS Drug Gilenya Positive in Long-Term Study Zacks
07:20AM  [$$] Novartis Deal Could Send Xoma Stock to $19 Barrons.com
07:10AM  Corporate News Blog - Leadership Change in Novartis as CEO Jimenez to Retire in 2018; Vasant Narasimhan Named His Successor ACCESSWIRE
Sep-05-17 04:37PM  Narasimhan to Replace Jimenez as Novartis (NVS) CEO in 2018 Zacks
08:53AM  Gilead Sciences Couldn't Have Timed its Splash Into CAR-T Better Motley Fool
07:15AM  Why Juno Therapeutics Shares Vaulted 46% Higher in August Motley Fool
07:00AM  3 Stocks to Watch on Tuesday: Boeing Co (BA), McDonalds Corporation (MCD) and Novartis AG (ADR) (NVS) InvestorPlace
06:58AM  Novartis CAR-T therapy was the first approved in U.S. heres how to invest in the space MarketWatch
06:44AM  Novartis CEO to step down next year CNBC Videos
12:03AM  [$$] Novartis CEO to Step Down in January The Wall Street Journal
12:00AM  Novartis Calls the Doctor to Push Breakthrough Drugs Forward Bloomberg
Sep-04-17 12:14PM  [$$] Novartis names chief to replace Jimenez who is to step down Financial Times
10:52AM  [$$] Novartis: doctor in the house Financial Times
10:31AM  Weekend roundup: Campbell in the soup | New cancer treatment | Exposing bad investment advice MarketWatch
09:48AM  Novartis names drugs chief as CEO to deliver return to growth Reuters
09:19AM  Novartis CEO Jimenez to step down early next year Associated Press
08:35AM  Novartis Calls for the Doctor Bloomberg
06:55AM  New CEO as Novartis bids for growth Reuters Videos
05:59AM  Novartis Names Narasimhan CEO as Jimenez Retires Bloomberg Video
04:30AM  Novartis CEO Joseph Jimenez Is Stepping Down Fortune
03:40AM  [$$] Novartis CEO to Step Down In January The Wall Street Journal
03:32AM  Novartis CEO Joe Jimenez to Step Down in 2018 TheStreet.com
01:48AM  [$$] Novartis CEO Joe Jimenez to Step Down in January The Wall Street Journal
01:23AM  Novartis CEO's decision to step down very sensible, ana... CNBC Videos
01:23AM  Novartis CEO Joseph Jimenez to retire in 2018 CNBC Videos
01:10AM  Novartis CEO Jimenez to Quit, Giving Reins to Harvard Doctor Bloomberg
Sep-01-17 08:27PM  3 Reasons Gilead Sciences Jumped to Buy Kite Pharma Motley Fool
05:24PM  [$$] Week in Review, September 2 Financial Times
01:04PM  Cancer Breakthroughs Can Quickly Become Tomorrow's Also-Ran Bloomberg
11:31AM  Novartis CEO: Here's How We Handled A Milestone In Pediatric Cancer Forbes
10:36AM  Ligand Pharmaceuticals Projects Higher Average Royalty Rate for Promacta Market Realist
09:09AM  Label Expansion Could Boost Promactas Revenues Going Forward Market Realist
09:06AM  Promacta: A Major Growth Driver for Ligand Pharmaceuticals in 2017 Market Realist
08:10AM  Today's Research Reports on Stocks to Watch: Seattle Genetics and Novartis ACCESSWIRE
07:57AM  Pharma Stock Roundup: Novartis CAR-T Drug Gets FDA Nod, Lilly Gives Baricitinib Update Zacks
07:37AM  Novartis on the Street: Analysts Recommendations after 2Q17 Market Realist
03:00AM  Profit on $475,000 Novartis cancer drug could be a while coming Reuters
Aug-31-17 09:00PM  Novartis $475,000 Price Tag Sets the Stage for a Price War With Gilead Sciences Motley Fool
02:14PM  Novartis CAR-T gene therapy, the first approved by FDA, to cost $475,000 MarketWatch
02:00PM  Read the Fine Print on the $475,000 Price of a Cancer Breakthrough Bloomberg
12:54PM  Novartis Cancer Drug Is Approved With $475,000 Price Tag Bloomberg Video
12:34PM  Changes in GlaxoSmithKlines Valuation after 2Q17 Market Realist
12:25PM  Profit on $475,000 Novartis cancer drug could be a while coming Reuters
11:51AM  Novartis (NVS) CAR-T Therapy Kymriah Receives FDA Approval Zacks
11:45AM  A medical breakthrough that hacks genes to fight cancer just got approved, and it's the beginning of 'a big new field of medicine' Business Insider
10:55AM  Gilead Sciences: No, the Novartis Approval Wasn't Good News Barrons.com
10:37AM  Understanding Novartiss Recent Developments after 2Q17 Market Realist
09:07AM  How Novartiss Alcon Eye Care Business Performed in 2Q17 Market Realist
09:01AM  A Cancer Doctor Weighs In On CAR-T, Precision Medicine And Pricing Debates Forbes
08:20AM  Today's Research Reports on Stocks to Watch: Mazor Robotics and Novartis ACCESSWIRE
07:38AM  How Novartiss Sandoz Performed in 2Q17 Market Realist
06:41AM  FDA approves new treatment for childhood leukemia CNBC Videos
Aug-30-17 07:40PM  Novartis's $475,000 Cancer Breakthrough Heralds New Era of Cures Bloomberg
07:40PM  Novartis's $475,000 cancer breakthrough heralds new era of cures Bloomberg
06:55PM  [$$] Torque Therapeutics Gathers $21 Million for Novel Cancer Cellular Therapies The Wall Street Journal
Novartis AG researches, develops, manufactures, and markets healthcare products worldwide. The company's Innovative Medicines segment offers patented prescription medicines to enhance health outcomes for patients and health-care providers. This segments also franchises ophthalmology, neuroscience, immunology and dermatology, respiratory, cardio-metabolic, and other medicines, as well as cell and gene therapies. The Sandoz segment offers active ingredients and finished dosage forms of pharmaceuticals for dermatology, respiratory and ophthalmic, cardiovascular, metabolism, central nervous system, pain, gastrointestinal, and hormonal therapies; active pharmaceutical ingredients and intermediates primarily antibiotics; protein or other biotechnology-based products; and cytotoxic products for the hospital markets, as well as biotechnology manufacturing services to other companies. The Alcon segment offers eye care products, including ophthalmic surgical equipment, instruments, disposable products, and intraocular lenses for use in surgical procedures to treat cataracts, vitreoretinal conditions, glaucoma, and refractive errors; and contact lenses and lens care products. The company has collaboration and licensing agreements with Xencor for the development of bispecific antibodies for treating cancer; and Surface Oncology to access four pre-clinical programs in immuno-oncology. It also has collaboration and licensing agreements with Intellia Therapeutics for the discovery and development of new medicines using CRISPR genome editing technology; and Caribou Biosciences for the development of drug discovery tools. In addition, the company has a clinical research collaboration with Bristol-Myers Squibb Company to investigate Opdivo (nivolumab) and Opdivo + Yervoy (ipilimumab) regimen in combination with Mekinist as a treatment option for metastatic colorectal cancer. Novartis AG was founded in 1895 and is headquartered in Basel, Switzerland.
Insider Trading Relationship Date Transaction Cost #Shares Value ($) #Shares Total SEC Form 4
Novartis Bioventures Ltd10% OwnerJul 05Buy15.00266,6674,000,0052,544,182Jul 05 06:05 PM
Novartis Bioventures Ltd10% OwnerJun 19Sale22.023,22070,8992,251,457Jun 20 04:41 PM
Novartis Bioventures Ltd10% OwnerJun 16Sale21.2453,2001,130,2072,254,677Jun 20 04:41 PM
Novartis Bioventures Ltd10% OwnerJun 08Sale22.0070015,4002,307,877Jun 12 04:12 PM
Novartis Bioventures Ltd10% OwnerJun 07Sale22.114,840106,9992,308,577Jun 08 04:33 PM
Novartis Bioventures Ltd10% OwnerJun 06Sale22.987,274167,1612,313,417Jun 08 04:33 PM
Novartis Bioventures Ltd10% OwnerJun 05Sale23.114,780110,4882,320,691Jun 06 04:27 PM
Novartis Bioventures Ltd10% OwnerJun 02Sale23.4714,867348,9492,325,471Jun 06 04:27 PM
Novartis Bioventures Ltd10% OwnerJun 01Sale23.8910,722256,1762,340,338Jun 02 04:25 PM
Novartis Bioventures Ltd10% OwnerMay 31Sale23.9435,539850,8962,351,060Jun 02 04:25 PM
Novartis Bioventures Ltd10% OwnerMay 26Sale25.145,300133,2672,386,599May 30 04:29 PM
Novartis Bioventures Ltd10% OwnerMay 25Sale25.00531,3252,391,899May 30 04:29 PM
Novartis Bioventures Ltd10% OwnerMay 24Sale25.0117,451436,3642,391,952May 25 04:57 PM
Novartis Bioventures Ltd10% OwnerMay 18Sale25.509,019229,9642,409,403May 22 06:50 PM
Novartis Bioventures Ltd10% OwnerMay 17Sale25.5122,534574,9012,418,422May 18 04:36 PM
Novartis Bioventures Ltd10% OwnerMay 16Sale26.3320,081528,7252,440,956May 18 04:36 PM
Novartis Bioventures Ltd10% OwnerMar 15Buy5.00560,0002,800,0005,805,550Mar 17 08:36 PM
Novartis Bioventures Ltd10% OwnerMar 01Sale20.917,778162,6582,461,037May 02 05:22 PM
Novartis Bioventures Ltd10% OwnerFeb 28Sale20.867,847163,6702,468,815May 02 05:22 PM
Novartis Bioventures Ltd10% OwnerFeb 27Sale20.9657,8441,212,3062,476,662May 02 05:22 PM
Novartis Bioventures Ltd10% OwnerFeb 24Sale20.935,398113,0002,534,506May 02 05:22 PM
Novartis Bioventures Ltd10% OwnerFeb 23Sale21.044,999105,1602,539,904May 02 05:22 PM
Novartis Bioventures Ltd10% OwnerFeb 22Sale21.8674916,3702,544,903May 02 05:22 PM
Novartis Bioventures Ltd10% OwnerOct 31Buy13.0084,6151,099,9952,545,652Oct 31 04:50 PM
Novartis Bioventures Ltd10% OwnerOct 31Sale13.003394,40762,575Oct 31 04:50 PM